Business
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris
New members bring deep experience in pancreatic, colorectal, and anal cancers to guide pelareorep’s development as a platform immunotherapy across GI tumors
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\nNew members bring deep experience in pancreatic, colorectal, and anal cancers to guide pelareorep’s development as a platform immunotherapy across GI tumors\n\n\nCompany continues to strengthen its clinical and strategic foundation to advance registration-enabling studies in high-value indications\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nOncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the expansion of its gastrointestinal (“GI”) Tumor Scientific Advisory Board (“SAB”) with the appointment of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris, three globally recognized experts in gastrointestinal oncology. The GI SAB was recently established to support Oncolytics’ growing portfolio of clinical programs in pancreatic, colorectal, and anal cancers and to guide the Company’s strategy as it advances pelareorep as a platform immunotherapy across GI tumors.\n\n\nDr. Eileen O’Reilly is the Winthrop Rockefeller Endowed Chair of Medical Oncology at Memorial Sloan Kettering Cancer Center (“MSK”) and an internationally recognized leader in pancreatic cancer research and treatment.\n\n\n“The data emerging with pelareorep across gastrointestinal cancers add to the growing evidence of immunotherapy’s potential in these diseases,” said Dr. O’Reilly. “The opportunity to help guide a program that has demonstrated durable responses and encouraging survival signals across multiple tumor types is an important one.”\n\n\nDr. Neil Segal is the Research Director of the Division of Gastrointestinal Oncology at MSK and an expert in translational oncology and biomarker-driven development.\n\n\n“Pelareorep’s immunomodulatory potential across solid tumors warrants further evaluation as a potential therapeutic approach,” said Dr. Segal. “I look forward to contributing scientific guidance as Oncolytics advances its clinical development program and explores collaborative opportunities.”\n\n\nDr. Van Morris is an Associate Professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston, TX, where he also serves as the Section Chief for Colorectal Cancer.\n\n\n“I have a strong belief in the potential of immunotherapies like pelareorep to help patients in the gastrointestinal cancer setting,” sai...